RU2014106966A - Пиразоло[3,4-с]пиридины и способы их применения - Google Patents
Пиразоло[3,4-с]пиридины и способы их применения Download PDFInfo
- Publication number
- RU2014106966A RU2014106966A RU2014106966/04A RU2014106966A RU2014106966A RU 2014106966 A RU2014106966 A RU 2014106966A RU 2014106966/04 A RU2014106966/04 A RU 2014106966/04A RU 2014106966 A RU2014106966 A RU 2014106966A RU 2014106966 A RU2014106966 A RU 2014106966A
- Authority
- RU
- Russia
- Prior art keywords
- heteroaryl
- cancer
- heterocyclyl
- nhch
- och
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 101150065749 Churc1 gene Proteins 0.000 claims abstract 43
- 102100038239 Protein Churchill Human genes 0.000 claims abstract 43
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims abstract 41
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims abstract 19
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 19
- 150000001875 compounds Chemical class 0.000 claims abstract 18
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 15
- 125000002947 alkylene group Chemical group 0.000 claims abstract 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims abstract 6
- 125000003118 aryl group Chemical group 0.000 claims abstract 3
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 2
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 11
- -1 azepanil Chemical group 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 4
- 125000003566 oxetanyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- DEZJKGVJDMAGPI-UHFFFAOYSA-N 4-(piperidin-4-ylmethyl)morpholine Chemical compound C1COCCN1CC1CCNCC1 DEZJKGVJDMAGPI-UHFFFAOYSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 125000003725 azepanyl group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 230000002124 endocrine Effects 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 108010083755 proto-oncogene proteins pim Proteins 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010048832 Colon adenoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 241000282806 Rhinoceros Species 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 208000025188 carcinoma of pharynx Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 239000003076 neurotropic agent Substances 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Соединение, выбранное из формулы I:и его стереоизомеры, геометрические изомеры, таутомеры или фармацевтически приемлемые соли, где:Rвыбирают из -CN, -CHCN, -CHCONH, -CONH, -CONHCH, -CON(СН), -NHCONH, C-C-карбоциклила, C-C-гетероциклила, C-C-гетероарила, -(C-C-гетероарил)-(C-C-гетероарила), -(C-C-гетероарил)-(C-C-гетероциклила), -(C1-C-гетероарил)-O-(C-C-гетероциклила), -(C-Cгетероарил)-O-(C-C-алкилен)-(C-C-гетероциклила), -(C-C-гетероарил)-NR-(C-C-гетероциклила) и -(C-C-гетероарил)-NR-(C-C-алкилен)-(C-C-гетероциклила);Rвыбирают из C-C-алкила, C-C-карбоциклила, C-C-гетероциклила, C-C-гетероарила, C-C-арила, -(C-C-арил)-(C-C-гетероциклила), -(C-C-алкилен)-(C-C-гетероциклила), -(C-C-алкилен)-NR(C-C-гетероциклила), -(C-C-алкилен)-NR-(C-C-алкилен)-(C-C-гетероциклила), -(C-C-гетероарил)-(C-C-гетероарила), -(C-C-гетероарил)-(C-C-гетероциклила), -(C-C-гетероарил)-(C-C-гетероциклил)-(C-C-гетероциклила), -(C-C-гетероарил)-NR-(C-C-гетероциклила), -(C-C-гетероарил)-(C-C-алкилен)-(C-C-гетероциклила), -(C-C-гетероарил)-NR-(C-C-алкилен)-(C-C-гетероциклила) и -(C-C-гетероарил)-NR-(C-C-алкилен)-(C-C-гетероарила);Rнезависимо выбирают из H и C-C-алкила, возможно содержащего в качестве заместителя F, Cl, CN, -COH, -СОСН, -COCH, -COC(СН), -СОСН(ОН)СН, -CONH, -CONHCH, -CON(СН), -NO, -NH, -NHCH, -N(СН), -NHCOCH, -N(СН)СОСН, -NHS(O)СН, -NHCHCHNH, -NHCHCHCHNH, -NHCHCHCHCHNH, -N(СН)С(СН)CONH, -N(CH)CHCHS(O)CH,=O, -OH, -OCH, -ОСНСНОСН, -OCHCHNH, -S(O)N(CH), -SCHи -S(O)CH;при этом алкил, алкенил, алкинил, алкилен, карбоциклил, гетероциклил, арил и гетероарил возможно содержат в качестве заместителя одну или более групп, независимо выбранных из F, CI, Br, I, -СН, -СНСН, -СН(СН), -СНСН(СН), -CHNH, -CHNHCH, -CHN(CH), -CHCHNH, -CHCHCHNH, -CHCHCHCHNH, -CHCH(CH)NH, -CHCONH, -CHOH, -CHCHOH, -C(CH)OH, -CH(OH)CH(CH), -C(CH)CHOH, -CHC(CH)OH, -CHCHSOCH, -CN, -CF, -COH, -COCH, -COCH, -COC(CH), -COCH(OH)CH, -CONH, -CONHCH, -CON(CH), -C(CH)CONH, -NO, -NH, -NHCH, -N(CH), -NHCOCH, -N(CH)COCH, -NHS(O)CH, -NHCHCHNH, -NHCHCHCHNH, -NHCHCHCHCHNH, -N(CH)C(CH)CONH, -N(CH)CHCHS(O)CH,=O, -OH, -OCH, -OCHCH
Claims (21)
1. Соединение, выбранное из формулы I:
и его стереоизомеры, геометрические изомеры, таутомеры или фармацевтически приемлемые соли, где:
R1 выбирают из -CN, -CH2CN, -CH2CONH2, -CONH2, -CONHCH3, -CON(СН3)2, -NHCONH2, C3-C12-карбоциклила, C2-C20-гетероциклила, C1-C20-гетероарила, -(C1-C20-гетероарил)-(C1-C20-гетероарила), -(C1-C20-гетероарил)-(C2-C20-гетероциклила), -(C1-C20-гетероарил)-O-(C2-C20-гетероциклила), -(C1-C20гетероарил)-O-(C1-C12-алкилен)-(C2-C20-гетероциклила), -(C1-C20-гетероарил)-NR3-(C2-C20-гетероциклила) и -(C1-C20-гетероарил)-NR3-(C1-C12-алкилен)-(C2-C20-гетероциклила);
R2 выбирают из C1-C12-алкила, C3-C12-карбоциклила, C2-C20-гетероциклила, C1-C20-гетероарила, C6-C20-арила, -(C6-C20-арил)-(C2-C20-гетероциклила), -(C1-C12-алкилен)-(C2-C20-гетероциклила), -(C1-C12-алкилен)-NR3(C2-C20-гетероциклила), -(C1-C12-алкилен)-NR3-(C1-C12-алкилен)-(C2-C20-гетероциклила), -(C1-C20-гетероарил)-(C1-C20-гетероарила), -(C1-C20-гетероарил)-(C2-C20-гетероциклила), -(C1-C20-гетероарил)-(C2-C20-гетероциклил)-(C2-C20-гетероциклила), -(C1-C20-гетероарил)-NR3-(C2-C20-гетероциклила), -(C1-C20-гетероарил)-(C1-C12-алкилен)-(C2-C20-гетероциклила), -(C1-C20-гетероарил)-NR3-(C1-C12-алкилен)-(C2-C20-гетероциклила) и -(C1-C20-гетероарил)-NR3-(C1-C12-алкилен)-(C1-C20-гетероарила);
R3 независимо выбирают из H и C1-C12-алкила, возможно содержащего в качестве заместителя F, Cl, CN, -CO2H, -СОСН3, -CO2CH3, -CO2C(СН3)3, -СОСН(ОН)СН3, -CONH2, -CONHCH3, -CON(СН3)2, -NO2, -NH2, -NHCH3, -N(СН3)2, -NHCOCH3, -N(СН3)СОСН3, -NHS(O)2СН3, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2CH2CH2CH2NH2, -N(СН3)С(СН3)2CONH2, -N(CH3)CH2CH2S(O)2CH3,=O, -OH, -OCH3, -ОСН2СН2ОСН3, -OCH2CH2NH2, -S(O)2N(CH3)2, -SCH3 и -S(O)2CH3;
при этом алкил, алкенил, алкинил, алкилен, карбоциклил, гетероциклил, арил и гетероарил возможно содержат в качестве заместителя одну или более групп, независимо выбранных из F, CI, Br, I, -СН3, -СН2СН3, -СН(СН3)2, -СН2СН(СН3)2, -CH2NH2, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NH2, -CH2CHCH2NH2, -CH2CHCH2CH2NH2, -CH2CH(CH3)NH2, -CH2CONH2, -CH2OH, -CH2CH2OH, -C(CH3)2OH, -CH(OH)CH(CH3)2, -C(CH3)2CH2OH, -CH2C(CH3)2OH, -CH2CH2SO2CH3, -CN, -CF3, -CO2H, -COCH3, -CO2CH3, -CO2C(CH3)3, -COCH(OH)CH3, -CONH2, -CONHCH3, -CON(CH3)2, -C(CH3)2CONH2, -NO2, -NH2, -NHCH3, -N(CH3)2, -NHCOCH3, -N(CH3)COCH3, -NHS(O)2CH3, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2CH2CH2CH2NH2, -N(CH3)C(CH3)2CONH2, -N(CH3)CH2CH2S(O)2CH3,=O, -OH, -OCH3, -OCH2CH2OCH3, -OCH2CH2NH2, -S(O)2N(CH3)2, -SCH3, -CH2OCH3, -S(O)2CH3, циклопропила, циклобутила, циклопентила, циклогексила, циклогептила, азетидинила, азепанила, оксетанила, пирролидинила, пиперазинила, пиперидинила, (пиперидин-4-ил)этила), пиранила, (пиперидин-4-илметила), морфолинометила и морфолина.
2. Соединение по п. 1, в котором R1 представляет собой C1-C20-гетероарил.
4. Соединение по п. 1, в котором R1 выбирают из -CN, -CH2CN, -CH2CONH2, -CONH2, -CONHCH3, -CON(СН3)2 и -NHCONH2.
5. Соединение по п. 1, в котором R2 представляет собой C1-C20-гетероарил.
6. Соединение по п. 1, в котором R2 представляет собой - (C1-C20-гетероарил)- (C2-C20-гетероциклил).
7. Соединение по п. 1, в котором R2 выбирают из следующих структур:
где волнистая линия обозначает место присоединения; и
R4 выбирают из F, Cl, Br, I, -СН3, -СН2СН3, -СН(СН3)2, -СН2СН(СН3)2, -CH2NH2, -CH2NHCH3, -CH2N(СН3)2, -CH2CH2NH2, -CH2CHCH2NH2, -CH2CHCH2CH2NH2, -СН2СН(СН3)NH2, -CH2CONH2, -СН2ОН, -СН2СН2ОН, -С(СН3)2ОН, -СН(ОН)СН(СН3)2, -С(СН3)2СН2ОН, -СН2С(СН3)2ОН, -CH2CH2SO2CH3, -CN, -CF3, -CO2H, -СОСН3, -CO2CH3, -CO2C(СН3)3, -СОСН(ОН)СН3, -CONH2, -CONHCH3, -CON(СН3)2, -С(СН3)2CONH2, -NO2, -NH2, -NHCH3, -N(СН3)2, -NHCOCH3, -N(СН3)СОСН3, -NHS(O)2СН3, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2CH2CH2CH2NH2, -N(СН3)С(СН3)2CONH2, -N(СН3)CH2CH2S(O)2СН3,=O, -ОН, -ОСН3, -ОСН2СН2ОСН3, -OCH2CH2NH2, -S(O)2N(СН3)2, -SCH3, -СН2ОСН3, -S(O)2СН3, циклопропила, циклобутила, циклопентила, циклогексила, циклогептила, азетидинила, азепанила, оксетанила, пирролидинила, пиперазинила, пиперидинила, (пиперидин-4-ил)этила), пиранила, (пиперидин-4-илметила), морфолинометила и морфолина; и
n равно 0, 1 или 2,
8. Соединение по п. 1, имеющее структуру формулы Ia:
где
R4 выбирают из F, Cl, Br, I, -СН3, -СН2СН3, -СН(СН3)2, -СН2СН(СН3)2, -СН2Н2, -CH2NHCH3, -CH2N(СН3)2, -CH2CH2NH2, -CH2CHCH2NH2, -CH2CHCH2CH2NH2, -СН2СН(СН3)NH2, -CH2CONH2, -СН2ОН, -СН2СН2ОН, -С(СН3)2ОН, -СН(ОН)СН(СН3)2, -С(СН3)2СН2ОН, -СН2С(СН3)2ОН, -CH2CH2SO2CH3, -CN, -CF3, -CO2H, -СОСН3, -CO2CH3, -CO2C(СН3)3, -СОСН(ОН)СН3, -CONH2, -CONHCH3, -CON(СН3)2, -С(СН3)2CONH2, -NO2, -NH2, -NHCH3, -N(СН3)2, -NHCOCH3, -N(СН3)СОСН3, -NHS(O)2СН3, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2CH2CH2CH2NH2, -N(СН3)С(СН3)2CONH2, -N(СН3)CH2CH2S(O)2СН3,=O, -ОН, -ОСН3, -ОСН2СН2ОСН3, -OCH2CH2NH2, -S(O)2N(СН3)2, -SCH3, -СН2ОСН3, -S(O)2СН3, циклопропила, циклобутила, циклопентила, циклогексила, циклогептила, азетидинила, азепанила, оксетанила, пирролидинила, пиперазинила, пиперидинила, (пиперидин-4-ил)этила), пиранила, (пиперидин-4-илметила), морфолинометила и морфолина; и
n равно 0, 1 или 2,
9. Соединение по п. 1, имеющее структуру формулы Ib:
где
R3 выбирают из H, C3-C12-карбоциклила и C1-C12-алкила, при этом карбоциклил и алкил возможно содержат в качестве заместителя F, Cl, CN -CO2H, -СОСН3, -CO2CH3, -CO2C(СН3)3, -СОСН(ОН)СН3, -CONH2, -CONHCH3, -CON(CH3)2, -NO2, -NH2, -NHCH3, -N(СН3)2, -NHCOCH3, -N(CH3)COCH3, -NHS(O)2СН3, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2CH2CH2CH2NH2, -N(СН3)С(СН3)2CONH2, -N(CH3)CH2CH2S(O)2CH3,=O, -OH, -ОСН3, -ОСН2СН2ОСН3, -OCH2CH2NH2, -S(O)2N(CH3)2, -SCH3 и -S(O)2СН3; и n равно 0, 1 или 2,
10. Соединение по п. 1, имеющее структуру формулы Ic:
где
R4 выбирают из F, Cl, Br, I, -СН3, -СН2СН3, -СН(СН3)2, -СН2СН(СН3)2, -CH2NH2, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NH2, -CH2CHCH2N42, -CH2CHCH2CH2NH2, -CH2CH(CH3)NH2, -CH2CONH2, -СН2ОН, -СН2СН2ОН, -С(СН3)2ОН, -СН(ОН)СН(СН3)2, -С(СН3)2СН2ОН, -СН2С(СН3)2ОН, -CH2CH2SO2CH3, -CN, -CF3, -CO2H, -СОСН3, -CO2CH3, -CO2C(СН3)3, -СОСН(ОН)СН3, -CONH2, -CONHCH3, -CON(СН3)2, -С(СН3)2CONH2, -NO2, -NH2, -NHCH3, -N(CH3)2, -NHCOCH3, -N(CH3)COCH3, -NHS(O)2CH3, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2CH2CH2CH2NH2, -N(CH3)С(CH3)2CONH2, -N(CH3)CH2CH2S(O)2СН3,=O, -OH, -OCH3, -OCH2CH2OCH3, -OCH2CH2NH2, -S(O)2N(CH3)2, -SCH3, -CH2OCH3, -S(O)2CH3, циклопропила, циклобутила, циклопентила, циклогексила, циклогептила, азетидинила, азепанила, оксетанила, пирролидинила, пиперазинила, пиперидинила, (пиперидин-4-ил)этила), пиранила, (пиперидин-4-илметила), морфолинометила и морфолина; и
n равно 0, 1 или 2,
11. Соединение по п. 1, выбранное из Таблицы 1.
12. Фармацевтическая композиция, включающая соединение по любому из пп. 1-11 и фармацевтически приемлемый носитель, скользящее вещество, разбавитель или эксципиент.
13. Фармацевтическая композиция по п. 12, дополнительно включающая второй хемотерапевтический агент.
14. Способ изготовления фармацевтической композиции, включающий комбинирование соединения по п. 1 с фармацевтически приемлемым носителем.
15. Способ лечения заболевания или расстройства, включающий введение терапевтически эффективного количества соединения по любому из пп. 1-11 пациенту, страдающему заболеваниями или расстройствами, выбранных из следующих: рак, иммунные расстройства, сердечно-сосудистое заболевание, вирусная инфекция, воспаление, метаболическое/эндокринное функциональные расстройства и нервные расстройства, опосредованные Pim-киназами.
16. Способ по п. 15, где указанное заболевание или расстройство представляет собой рак, выбранный из следующих: множественная миелома, рак молочной железы, яичника, шейки матки, простаты, семенников, урогенитального тракта, пищевода, гортани; глиобластома, нейробластома; рак желудка, рак кожи, кератоакантома, рак легких, эпидермоидный рак, крупноклеточный рак, не-мелкоклеточный рак легких (NSCLC), мелкоклеточный рак, аденокарцинома легких, рак костей, рак толстой кишки, аденома, рак поджелудочной железы, аденокарцинома, рак щитовидной железы, фолликулярная карцинома, недифференцированная карцинома, папиллярная карцинома, семинома, меланома, саркома, рак мочевого пузыря, рак печени и желчной протоки, рак почек, панкреатический рак, миелоидные расстройства, лимфомы, «волосатые клетки», рак ротовой полости, носоглоточный рак, рак глотки, губ, языка, рта, тонкого кишечника, рак толстого кишечника и прямой кишки, толстого кишечника, прямой кишки, рак мозга и центральной нервной системы, болезнь Ходжкина, лейкоз, рак бронхов, рак щитовидной железы, печени и внутрипеченочной желчной протоки, печеночно-клеточный рак, рак желудка, глиома/глиобластома, внутриматочный рак, меланома, рак почек и почечной лоханки, рак мочевого пузыря, рак тела матки, рак шейки матки, острый миелогенный лейкоз, хронический миелогенный лейкоз, лимфоцитарный лейкоз, миелоидный лейкоз, рак ротовой полости и глотки, неходжкинская лимфома, меланома и ворсинчатая аденома толстой кишки.
17. Способ по п. 16, дополнительно включающий введение еще одного терапевтического агента, выбранного из хемотерапевтического агента, противовоспалительного агента, иммуномодулирующего агента, нейротропного фактора, агента для лечения сердечно-сосудистого заболевания, агента для лечения заболевания печени, противовирусного агента, агента для лечения расстройств крови, агента для лечения диабета и агента для лечения иммунодефицитных расстройств.
18. Способ по п. 17, в котором дополнительный терапевтический агент выбирают из следующих: дексаметазон, тиоТЕПА, доксорубицин, винкристин, ритуксимаб, циклофосфамид, преднизон, мелфалан, леналидомид, бортезомиб, рапамицин и цитарабин.
19. Набор для лечения состояния, опосредованного Pim-киназами, включающий:
a) первую фармацевтическую композицию, включающую соединение по п. 1; и
b) инструкцию по применению.
20. Применение соединения по любому из пп. 1-11 для изготовления лекарственного средства для лечения рака, иммунного расстройства, сердечно-сосудистого заболевания, вирусной инфекции, воспаления, метаболического/эндокринного функционального расстройства и нервного расстройства, при этом действие такого лекарственного средства опосредовано Pim-киназой.
21. Соединение по любому из пп. 1-11 для применения в лечении заболеваний или расстройств, выбранных из рака, иммунного расстройства, сердечнососудистого заболевания, вирусной инфекции, воспаления, метаболического/эндокринного функционального расстройства и нервного расстройства, и опосредованных Pim-киназой.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161522857P | 2011-08-12 | 2011-08-12 | |
US61/522,857 | 2011-08-12 | ||
PCT/EP2012/065643 WO2013024002A1 (en) | 2011-08-12 | 2012-08-10 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2014106966A true RU2014106966A (ru) | 2015-09-20 |
RU2638116C2 RU2638116C2 (ru) | 2017-12-15 |
Family
ID=46717823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014106966A RU2638116C2 (ru) | 2011-08-12 | 2012-08-10 | Пиразоло[3,4-с]пиридины и способы их применения |
Country Status (10)
Country | Link |
---|---|
US (2) | US9260425B2 (ru) |
EP (1) | EP2742046A1 (ru) |
JP (1) | JP6133291B2 (ru) |
KR (1) | KR20140071361A (ru) |
CN (1) | CN103874700B (ru) |
BR (1) | BR112014003296A2 (ru) |
CA (1) | CA2838784A1 (ru) |
MX (1) | MX355852B (ru) |
RU (1) | RU2638116C2 (ru) |
WO (1) | WO2013024002A1 (ru) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
ME03332B (me) | 2011-09-14 | 2019-10-20 | Samumed Llc | Indazol-3-karboksamidi i njihova upotreba kao inhibitora signalnog puta wnt/b-katenina |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
DK3176170T3 (en) | 2012-06-13 | 2019-01-28 | Incyte Holdings Corp | SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS |
KR20150028999A (ko) | 2012-06-27 | 2015-03-17 | 에프. 호프만-라 로슈 아게 | 5-아자인다졸 화합물 및 이의 사용 방법 |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
EP2943198B1 (en) | 2013-01-08 | 2019-07-17 | Samumed, LLC | 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof |
CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
BR122019024759B1 (pt) | 2013-01-15 | 2022-02-08 | Incyte Holdings Corporation | Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos |
SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
US9718818B2 (en) | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
SG11201601259YA (en) | 2013-08-23 | 2016-03-30 | Incyte Corp | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016065587A1 (en) * | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Pyrazole orexin receptor antagonists |
WO2016095089A1 (en) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
WO2016095088A1 (en) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
EP3617205B1 (en) | 2015-02-20 | 2021-08-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023975A1 (en) * | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023980A1 (en) * | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
US10188634B2 (en) | 2015-08-03 | 2019-01-29 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
US10226453B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10206908B2 (en) * | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
WO2017045955A1 (en) * | 2015-09-14 | 2017-03-23 | Basf Se | Heterobicyclic compounds |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
CN105213391B (zh) * | 2015-10-19 | 2018-05-18 | 青岛市中心医院 | 一种治疗肝癌的药物组合物及其应用 |
US10544139B2 (en) | 2015-11-06 | 2020-01-28 | Samumed, Llc | Treatment of osteoarthritis |
CA3026076A1 (en) | 2016-06-01 | 2017-12-07 | Samumed, Llc | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
CN115819417A (zh) * | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
MX2019004616A (es) | 2016-10-21 | 2019-11-21 | Samumed Llc | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. |
MA46696A (fr) | 2016-11-07 | 2019-09-11 | Samumed Llc | Formulations injectables à dose unique prêtes à l'emploi |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3672973A4 (en) * | 2017-08-22 | 2021-05-26 | JS Innopharm (Shanghai) Ltd. | HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
ES2914377T3 (es) * | 2017-10-27 | 2022-06-10 | Bayer Ag | Derivados novedosos de pirazolo-pirrolo-pirimidin-diona como inhibidor de P2X3 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
CR20200421A (es) | 2018-02-20 | 2021-01-26 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el càncer |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
TW201940483A (zh) * | 2018-03-12 | 2019-10-16 | 美商艾伯維有限公司 | 酪胺酸激酶2介導的傳訊之抑制劑 |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
AU2019262579A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Salts of an FGFR inhibitor |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
CN110201719B (zh) * | 2019-06-06 | 2020-04-21 | 南京科技职业学院 | 一种制药污水治理方法 |
CN112142744A (zh) * | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
JP2023505257A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤の誘導体 |
US11193891B2 (en) | 2019-12-20 | 2021-12-07 | Robert Bosch Gmbh | Receptors and spacers for a fluorescence-based lead ion chemosensor |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4166556A4 (en) * | 2020-07-13 | 2024-06-26 | Beijing Tide Pharmaceutical Co., Ltd. | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR |
EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2024029583A1 (ja) * | 2022-08-05 | 2024-02-08 | 国立研究開発法人理化学研究所 | 新規ピラゾール誘導体及びその用途 |
US11976079B1 (en) | 2023-12-15 | 2024-05-07 | King Faisal University | Pyrazino[1′,2′:1,5]pyrazolo[4,3-b][1,6]naphthyridines compounds as CK2 inhibitors |
US11987581B1 (en) | 2023-12-19 | 2024-05-21 | King Faisal University | Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acids as CK2 inhibitors |
US12024518B1 (en) | 2023-12-20 | 2024-07-02 | King Faisal University | Pyrazolo[4,3-C][1,6]naphthyridines as CK2 inhibitors |
US11964974B1 (en) | 2024-01-08 | 2024-04-23 | King Faisal University | Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-3-carboxylic acids as CK2 inhibitors |
US11981676B1 (en) | 2024-01-16 | 2024-05-14 | King Faisal University | Pyrazolo[4,3-c][2,6]naphthyridines as CK2 inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
GB9423460D0 (en) | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
MXPA03001420A (es) | 2000-08-14 | 2004-01-26 | Johnson & Johnson | Pirazoles sustituidos. |
ATE402699T1 (de) | 2000-09-06 | 2008-08-15 | Ortho Mcneil Pharm Inc | Verwendung von substituierten pyrazolen zur behandlung von allergien |
US7429609B2 (en) | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
CN104892582B (zh) | 2005-10-07 | 2019-09-27 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 |
NZ576234A (en) * | 2006-11-06 | 2011-06-30 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
SG182187A1 (en) * | 2007-06-08 | 2012-07-30 | Abbott Gmbh & Co Kg | 5-heteroaryl substituted indazoles as kinase inhibitors |
US20110046127A1 (en) * | 2007-11-08 | 2011-02-24 | Paolo Pevarello | Imidazopyridazines for Use as Protein Kinase Inhibitors |
KR100906571B1 (ko) * | 2008-06-29 | 2009-07-06 | 한창섭 | 광소자를 이용한 반구형 포인팅 장치 |
WO2010022081A1 (en) * | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
AU2011338389A1 (en) * | 2010-12-09 | 2013-06-13 | Amgen Inc. | Bicyclic compounds as Pim inhibitors |
-
2012
- 2012-08-10 EP EP12748670.2A patent/EP2742046A1/en not_active Withdrawn
- 2012-08-10 KR KR1020147006423A patent/KR20140071361A/ko active IP Right Grant
- 2012-08-10 JP JP2014524387A patent/JP6133291B2/ja not_active Expired - Fee Related
- 2012-08-10 BR BR112014003296A patent/BR112014003296A2/pt not_active Application Discontinuation
- 2012-08-10 CN CN201280050370.5A patent/CN103874700B/zh not_active Expired - Fee Related
- 2012-08-10 CA CA2838784A patent/CA2838784A1/en not_active Abandoned
- 2012-08-10 RU RU2014106966A patent/RU2638116C2/ru not_active IP Right Cessation
- 2012-08-10 MX MX2014001239A patent/MX355852B/es active IP Right Grant
- 2012-08-10 WO PCT/EP2012/065643 patent/WO2013024002A1/en active Application Filing
- 2012-08-10 US US13/571,595 patent/US9260425B2/en not_active Expired - Fee Related
-
2016
- 2016-02-16 US US15/044,231 patent/US9850239B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103874700A (zh) | 2014-06-18 |
RU2638116C2 (ru) | 2017-12-15 |
US20160159797A1 (en) | 2016-06-09 |
JP6133291B2 (ja) | 2017-05-24 |
BR112014003296A2 (pt) | 2017-03-14 |
CA2838784A1 (en) | 2013-02-21 |
US9850239B2 (en) | 2017-12-26 |
KR20140071361A (ko) | 2014-06-11 |
US20130039906A1 (en) | 2013-02-14 |
EP2742046A1 (en) | 2014-06-18 |
US9260425B2 (en) | 2016-02-16 |
JP2014521711A (ja) | 2014-08-28 |
WO2013024002A1 (en) | 2013-02-21 |
CN103874700B (zh) | 2018-03-30 |
MX355852B (es) | 2018-05-02 |
MX2014001239A (es) | 2014-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014106966A (ru) | Пиразоло[3,4-с]пиридины и способы их применения | |
RU2014153800A (ru) | Соединения 5-азаиндазола и способы их применения | |
RU2014114973A (ru) | Пиразол-4-ил-гетероциклил-карбоксамидные соединения и способы применения | |
ES2610825T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
RU2010154428A (ru) | Пуриновые соединения, ингибирующие рi3к и способы применения | |
ES2899461T3 (es) | Inhibidores heterocíclicos de glutaminasa | |
RU2687060C2 (ru) | Фармацевтические соединения | |
RU2008145663A (ru) | Производное тиено[3,2-d]пиримидина в качестве ингибитора фосфатидилинозитол-3-киназы (рi3к) | |
RU2013138835A (ru) | Гетероциклические соединения в качестве ингибиторов pi3 киназы | |
RU2014121074A (ru) | Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона | |
RU2012117398A (ru) | Бензоксазепиновые ингибиторы pi3 и способы применения | |
JP2011521968A5 (ru) | ||
JP2017523991A (ja) | グルタミナーゼ阻害剤の結晶形態 | |
KR20170131650A (ko) | 글루타미나제 억제제의 투여 방법 | |
RU2010133979A (ru) | Синтез лактонов резорциловой кислоты, используемых в качестве терапевтических агентов | |
RU2013104038A (ru) | СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ PI3K p110 ДЕЛЬТА ПУРИНОВЫЕ СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
RU2003137007A (ru) | Новые пиридилцианогуанидиновые соединения | |
CA2550350A1 (en) | 2-(hetero)aryl-substituted tetrahydroquinoline derivatives | |
CN115427042A (zh) | 组合 | |
WO2019222238A2 (en) | Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
JP2023507797A (ja) | 組み合わせ | |
RU2016137761A (ru) | Оксепан-2-ил-пиразол-4-ил-гетероциклил-карбоксамиды и способы их применения | |
JP2013525290A5 (ru) | ||
JP2018535995A (ja) | 癌を治療するためのピリミド−ピリダジノンの使用 | |
WO2023183520A1 (en) | Compositions and methods for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190811 |